Executive Director - Global Patient Safety Sciences Delivery
About the job
- A minimum M.D., P.A., Ph.D., or Pharm.D. degree is required, along with board certification or equivalent in a relevant clinical specialty.
- At least 17 years of total experience in pharmacovigilance or relevant clinical experience in the pharmaceutical industry is required.
- At least 6 years of team leadership and people management experience is required.
- Strong attention to detail and the ability to assess and optimize Safety Operations processes, drive consistency, and ensure high-quality, compliant execution across activities are required.
- Strong leadership capabilities and presence, interpersonal, verbal and written communication skills, organizational and workload planning skills, and the ability to manage multiple projects simultaneously are required.
- Define the strategy to standardize and ensure consistency in the execution of core activities across all products and therapeutic areas through common practices, processes, and templates.
- Oversee relevant training programs for Global Patient Safety Safety Sciences, including a standardized training curriculum, proficiency matrix, and knowledge management repository.
- Enable the Global Capability Center to operate more efficiently and scale with business demands.
- Develop innovative approaches to delivering core activities that integrate new technologies, including artificial intelligence.
- Ensure compliance and quality management of Safety Sciences Operations activities, including compliance with regulations and establishment of standard operating procedures and associated monitoring tools.
- Oversee signal detection coordination and the signal management process across all therapeutic areas, including Safety Monitoring Team, Safety Surveillance Plan, and Signal Evaluation Report activities.
- Coordinate and support high-quality, timely, and compliant benefit-risk assessments for periodic safety reports, including Development Safety Update Reports and Periodic Safety Update Reports.
- Support Safety Sciences Strategy in contributing Medical and Safety perspectives to the Global Patient Safety portfolio of documents, including Aggregate Report Management, Risk Management Plans, and Safety Management Plans, where required.
- Set and oversee the framework for aggregate safety data analysis to ensure effective coordination and delivery.
- Serve as the strategic point of contact to enable Safety Sciences operational delivery in partnership with Therapeutic Area Heads and Global Patient Safety Leads.
- Partner with Clinical, Regulatory, Medical Affairs, Biostatistics, and Data Management interfaces.
- Build, coach, and scale a high-performing team and drive succession planning and talent pipelines.
- Lead talent strategy and leadership development initiatives that strengthen capabilities across the organization.
- Preferred experience with oversight of operations within a global patient safety organization.
- An MBA is an advantage.
About the company
Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Mount Pleasant, New York
Founded
1988
Get referred to Regeneron Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 30, 2026 Q2 sales rose 17%; Dupixent, Libtayo, and EYLEA HD hit records.
- April 2026 FDA and European approvals expanded Dupixent CSU use and EYLEA HD dosing flexibility.
- November 2026 cemdisiran PDUFA and year-end EYLEA HD syringe approval create near-term catalysts.
What critics are saying
- May 15, 2026 fianlimab melanoma failure sparked a securities class action over an $11 billion wipeout.
- EYLEA faces biosimilar pressure after May 2024 U.S. exclusivity expiration, squeezing ophthalmology growth.
- Customer concentration remains brutal: two distributors drove roughly 77% of 2025 gross product revenue.
What makes Regeneron Pharmaceuticals unique
- Dupixent and EYLEA HD still anchor Regeneron’s multi-billion-dollar co-commercialized franchise.
- September 30, 2026 Sanofi pact adds four long-acting antibodies and $1 billion upfront.
- Regeneron’s proprietary antibody and RNA platforms keep generating partnered and internal pipeline shots.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 12%2 year growth
↑ 12%Regeneron Pharmaceuticals' stock has declined roughly 1% this year, despite being a strong long-term performer. The biotech company will report third-quarter earnings on 30 October, which could provide a catalyst for the struggling share price. When Regeneron last reported results in July, revenue totalled $4.3 billion, up 17% year-over-year. Global sales of Dupixent and Libtayo rose 38% and 30% respectively, whilst Eylea HD revenue in the US climbed 52%. The strong figures pushed the stock to a new 52-week high in early September. The company has roughly 50 product candidates in development. Regeneron trades at 19 times trailing earnings and less than 15 times forward earnings, compared to the S&P 500's multiples of 23 and 20 respectively.
Why this Regeneron eye rival just catapulted more than 120%. * ALLISON GATLIN * Updated 09:58 AM ET 09/28/2026 Kodiak Sciences (KOD) stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' (REGN) blockbuster eye drug, Eylea. Kodiak tested its drugs, Zenkuda and KSI-501, in patients with wet age-related macular degeneration. In this condition, abnormal blood vessels grow under the retina and leak fluid or blood, causing a rapid loss of central vision. Investors Are Rotating Into Healthcare. Here's Why. Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Investors Are Rotating Into Healthcare. Here's Why. See All Videos In the study, both Zenkuda and the earlier-stage drug, KSI-501, proved to be non-inferior to aflibercept after a year of treatment. Aflibercept is the chemical behind Eylea. Kodiak stock soared more than 120% to 72.47 in morning trades. Shares opened at a four-year high. Regeneron stock slipped 2.5% to 768.33. Both drugs show promise. Evercore ISI analyst Umer Raffat says investors only expected a "win" for Zenkuda which, like Eylea, works to block VEGF. VEGF, or anti-vascular endothelial growth factor, is a protein that leads to abnormal blood vessel growth. Eylea uses the same mechanism. But the earlier-stage KSI-501 also showed promise. KSI-501 blocks VEGF and IL-6, an inflammatory protein linked to the development and severity of wet age-related macular degeneration, or wet AMD. Zenkuda showed "meaningful vision gains as well as rapid and sustained retinal drying" for 54% on patients on every-six-months dosing. Zenkuda is given as an injection in the eye. "Today's results are deeply satisfying," Kodiak Chief Medical Officer J. Pablo Velazquez-Martin said in a written statement. "Four years and seven months after our first Phase 3 readout, Zenkuda's profile has come fully into focus through rigorous science, disciplined learning and thoughtful execution." KSI-501, also called tabirafusp alfa tedromer, met the study's vision goal. Kodiak Sciences is starting the Phase 3 study and accelerating enrollment in a study of patients with diabetic macular edema. The company is further planning to ask the Food and Drug Administration to approve Zenkuda in the fourth quarter. Dosing is the 'cherry on top' Raffat called the every-six-months dosing the "cherry on top" for Kodiak Sciences. That company used a strict "treat-to-dry" retreatment criteria. So, for 54% of patients, the results were durable for six months after the injection. The drugs also proved safe and tolerable. But the single most important line in the press release comes from Dr. Charles Wykoff, chairman of research at the Retina Consultants of Texas and a professor of clinical ophthalmology and deputy chair of ophthalmology at the Blanton Eye Institute. Wykoff, Raffat said, "is one of the most prolific retina trialists." "The Zenkuda results exceeded my expectations," Wykoff said. Dr. David Brown, chief medical officer for Retina Consultants of America, said the "holy grail" in treating wet AMD is finding something that delivers "robust anatomic disease control and maximal vision gains, sustained with less frequent dosing." In this way, the results of the study are "truly impressive," he said in a written statement. IBD newsletters. Get exclusive IBD analysis and actionable news daily. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD. YOU MAY ALSO LIKE:
Regeneron Pharmaceuticals, Inc. (REGN) presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum transcript. 162.3K Followers Regeneron Pharmaceuticals, Inc. (REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Jeffrey Walch - Bernstein Institutional Services LLC, Research Division Presentation Jeffrey Walch Bernstein Institutional Services LLC, Research Division Thank you so much for our next conversation with health care leaders and disruptors. I have the pleasure of speaking with Regeneron Pharmaceuticals. My name is Jeffrey Walch. I'm one of the analysts at Bernstein, I cover U.S. Biotechnology. And I'm very excited today to talk to 2 of the senior leaders at Regeneron, Chris Fenimore, EVP, Finance and CFO; and Ryan Crowe, SVP, Investor Relations. Before we kick off, I think, Ryan, you have something to read. Ryan Crowe Senior Vice President of Investor Relations & Strategic Analysis I sure do, Jeffrey. Thank you so much for having us. And I'll just briefly read a forward-looking statement reminder that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. And with that, Jeffrey, why don't we hop into your questions? Question-and-Answer Session Jeffrey Walch Bernstein Institutional Services LLC, Research Division Perfect. Well, thank you once again, both of you for chatting with us today. I'll sort of ask the question and whoever or both of you that would like to answer, feel free to do so. So first off, congrats on
Novo Nordisk and Regeneron Pharmaceuticals represent distinct pharmaceutical investment opportunities. Novo Nordisk specialises in metabolic disorders, particularly diabetes and obesity treatments, serving patients in roughly 170 countries with a workforce of about 68,800. In fiscal 2025, Novo Nordisk generated nearly $47.7 billion in revenue, up 6.4% year-over-year, with net income of approximately $15.8 billion. The company's net margin stood at 33.1%, whilst its debt-to-equity ratio was 0.7x. Free cash flow reached nearly $4.5 billion. Regeneron focuses on treatments for eye diseases, cancer, and inflammatory conditions using proprietary technologies. The company maintains strategic partnerships with Sanofi and Bayer. In July 2026, Regeneron expanded its cancer therapy pipeline through collaboration with Telix Pharmaceuticals. Notably, two distributors accounted for roughly 77% of Regeneron's gross product revenue in 2025, creating customer concentration risk.
Novo Nordisk vs. Regeneron Pharmaceuticals: which healthcare stock is a better buy in 2026? Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now. By Sara Appino - Updated Sep 15, 2026 at 8:49AM EST Key points. * Novo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies. * Regeneron Pharmaceuticals maintains a strong foothold in ophthalmology and immunology while expanding its pipeline through strategic collaborations. * Which of these established healthcare leaders is the better addition to your 2026 investment strategy? * 10 stocks The Motley Fool, LLC like better than Novo Nordisk" The race for pharmaceutical dominance often centers on chronic disease management. For investors, deciding between Novo Nordisk (NVO -2.01%) and Regeneron Pharmaceuticals (REGN -2.38%) requires a close look at their unique market strengths. Novo Nordisk focuses heavily on metabolic disorders, particularly diabetes and weight loss, where it holds a massive global share. Regeneron leverages its proprietary technologies to develop treatments for eye diseases, cancer, and inflammatory conditions. Comparing these two giants reveals different approaches to growth and risk. NVO & REGN: performance comparison. NVO (Novo Nordisk) REGN (Regeneron Pharmaceuticals) Key financial metrics. NVO - Novo Nordisk - 2.01 % (- $ 0.88) REGN - Regeneron Pharmaceuticals - 2.38 % (- $ 18.88) Market Cap 52wk Range $ 35.12 - $ 64.16 Gross Margin Dividend & Yield $1.80 (4.13%) Market Cap 52wk Range $ 541.00 - $ 859.34 Gross Margin Dividend & Yield $3.70 (0.47%) The case for Novo Nordisk. Novo Nordisk operates as a specialized leader among pharmaceutical stocks focusing on chronic disease care. Its primary focus remains on diabetes and obesity, where it provides essential medicines like insulin and GLP-1 treatments to patients in roughly 170 countries. Its latest annual report, filed for 2025, noted a workforce of approximately 68,800 people dedicated to these therapeutic areas. While major customers are not specifically disclosed in SEC filings, the company relies on a diverse base of healthcare providers and distributors globally. In FY 2025, revenue reached nearly $47.7 billion, representing a 6.4% increase over the previous year. This growth follows a significant expansion in its obesity care portfolio during prior fiscal periods. The firm reported net income of close to $15.8 billion for the year. This resulted in a net margin of approximately 33.1%. A net margin measures how much profit a company keeps for every dollar of sales generated after all expenses are paid. As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.7x. This metric compares total liabilities to shareholder equity to assess financial leverage. The current ratio, which measures the ability to pay short-term obligations with short-term assets, sits at approximately 0.8x. For the fiscal year, free cash flow was nearly $4.5 billion. Free cash flow is the cash a business generates after paying for its operations and capital expenditures. The case for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals focuses on inventing and commercializing medicines for serious conditions, including eye diseases and rare genetic disorders. The company relies on a concentrated group of distributor customers, with two entities accounting for roughly 77% of gross product revenue in 2025. Customer concentration like this adds a layer of risk to the business. To manage its global presence, the firm maintains strategic partnerships with Sanofi (SNY -1.62%) and Bayer for its lead products. In July 2026, it expanded its pipeline by collaborating with Telix Pharmaceuticals (TLX +9.76%) for cancer therapies. In FY 2025, revenue reached approximately $14.3 billion, which was a 1% increase over the previous fiscal year. It reported net income of nearly $4.5 billion for the period. This produced a net margin of roughly 31.4%, showing that the company retains nearly a third of its revenue as profit. The company has maintained steady profitability despite facing increased competition in its core therapeutic areas. As of its December 2025 balance sheet, the debt-to-equity ratio is close to 0.1x, indicating a very low level of total debt relative to equity. The current ratio stands at approximately 4.1x, suggesting a high degree of liquidity for meeting short-term debts. For the fiscal year, free cash flow was nearly $4.1 billion. This represents the actual cash available to the company after it has funded its ongoing operations and necessary equipment purchases. Risk profile comparison. Novo Nordisk faces risks primarily associated with its heavy reliance on the metabolic health market. As competition in the GLP-1 space intensifies from rivals like Amgen (AMGN -1.47%) and AstraZeneca (AZN -0.74%), pricing pressures could impact future growth. Additionally, the company must manage complex global supply chains to meet the soaring demand for its injectable treatments. Regulatory shifts in drug pricing, particularly in the United States, also pose a continuous threat to its high net margins. Where to invest $1,000 right now. When its analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 949% - a market-crushing outperformance compared to 212% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now... *Stock Advisor returns as of September 14, 2026 Regeneron faces significant revenue concentration, as it is highly dependent on sales of EYLEA and Dupixent. Biosimilar competition began impacting EYLEA sales following the expiration of its U.S. regulatory exclusivity in May 2024. The company is also navigating multiple securities fraud class action lawsuits alleging that investors were misled about clinical trial risks. Furthermore, Regeneron relies heavily on Sanofi and Bayer for commercialization, and any disputes with these partners could disrupt operations. Regulatory delays for candidates like itepekimab also present hurdles to its product pipeline. Valuation comparison. Regeneron appears to trade at a slight premium based on its P/S ratio, while Novo Nordisk offers a lower multiple relative to its Forward P/E and future earnings estimates. | Metric | Novo Nordisk | Regeneron Pharmaceuticals | | Forward P/E | 12.5x | 14.3x | | P/S ratio | 4.0x | 5.6x | Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers. Which stock would I buy in 2026? I'd go with Regeneron. Its most recent quarter was one of the strongest in the company's history, with every major drug hitting record sales simultaneously. Dupixent grew at an extraordinary pace across all nine of its approved uses, EYLEA HD surpassed its older predecessor in U.S. sales for the first time, and Libtayo posted record global revenue. The company beat earnings estimates by a wide margin and is entering the second half of the year with a step-up in collaboration revenue from its Sanofi partnership. That is a business firing across every product line at once. Novo Nordisk is not without its strengths. The Wegovy pill captured the vast majority of the U.S. oral obesity market since launch, treating more patients than ever before, and the company raised its full-year outlook. But pricing pressure from the U.S. government, reduced Medicaid coverage for obesity drugs, and intensifying competition from Eli Lilly are creating headwinds that are expected to weigh on results through the rest of the year. For investors with patience and a long horizon, Regeneron's diversified, multi-drug growth story is a more comfortable foundation than a company navigating significant pricing and competitive pressure on its most important product. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $5,000 at the time of its recommendation, you'd have $2,165,800!* Or when Nvidia made this list on April 15, 2005... if you invested $5,000 at the time of its recommendation, you'd have $6,481,270!* Now, it's worth noting Stock Advisor's total average return is 949% - a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of September 15, 2026.